2015
DOI: 10.1016/j.jval.2015.09.1393
|View full text |Cite
|
Sign up to set email alerts
|

The Budget Impact Of An Inhaler With Improved Features Compared To Spiriva® Handihaler® For The Management Of Chronic Obstructive Pulmonary Disease (Copd) In The Uk: Estimated Impact On Unscheduled Healthcare Costs And Inhaler Satisfaction

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Their model also anticipated a total drug cost savings of €53.66 million and additional savings of €4.12 million because of the progression in inhalation technique. Regarding other inhalation devices, Nicolai et al 40 assessed the potential economic impact of introducing an inhaler with improved features compared to Spiriva ® Handihaler ® to treat COPD in the UK. The potential budgetary impact achieved by using the new inhaler instead of Handihaler is calculated as €104.91 per patient and €16.69 million for the UK COPD population per year.…”
Section: Discussionmentioning
confidence: 99%
“…Their model also anticipated a total drug cost savings of €53.66 million and additional savings of €4.12 million because of the progression in inhalation technique. Regarding other inhalation devices, Nicolai et al 40 assessed the potential economic impact of introducing an inhaler with improved features compared to Spiriva ® Handihaler ® to treat COPD in the UK. The potential budgetary impact achieved by using the new inhaler instead of Handihaler is calculated as €104.91 per patient and €16.69 million for the UK COPD population per year.…”
Section: Discussionmentioning
confidence: 99%